Improved Insulin Sensitivity With Angiotensin Receptor Neprilysin Inhibition in Individuals With Obesity and Hypertension
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Natriuretic peptide (NP) deficiency and sustained renin‐angiotensin system activation are associated with impaired oxidative metabolism and predispose to type‐2 diabetes. We hypothesized that sacubitril/valsartan (LCZ696), which augments NP through neprilysin inhibition while blocking angiotensin II type‐1 (AT 1)‐receptors, improves insulin sensitivity, lipid mobilization, and oxidation. After 8 weeks of treatment of obese patients with hypertension, sacubitril/valsartan 400 mg q.d., but not amlodipine 10 mg q.d., was associated with a significant increase from baseline in the insulin sensitivity index (hyperinsulinemic‐euglycemic clamp), and tended to be higher in patients treated with sacubitril/valsartan compared to amlodipine. Abdominal adipose tissue interstitial glycerol concentrations increased with sacubitril/valsartan, but decreased with amlodipine. Whole‐body lipolysis and substrate oxidation did not change with either treatment. Results confirm that sacubitril/valsartan treatment leads to a metabolic benefit in the study population and supports the relevance of neprilysin inhibition along with AT 1‐receptor blockade in the regulation of human glucose and lipid metabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957 · cited 2×
“Sacubitril/valsartan, a novel angiotensin receptor neprilysin inhibitor, was recently approved in the United States, Europe, and many other countries to reduce the risk of cardiovascular death and hospitalizations in patients with chronic heart failure (New York Heart Association classes II–IV) and reduced ejection fr…”
BackgroundObesity-Induced Hypertension: Interaction of Neurohumoral and Renal Mechanisms
Hall, J. E., do Carmo, J. M., da Silva, A. A., Wang, Z., & Hall, M. E. (2015) · Circulation Research · doi:10.1161/circresaha.116.305697 · Cited by 1,360
Lipid-induced insulin resistance: unravelling the mechanism
Samuel, V. T., Petersen, K. F., & Shulman, G. I. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60408-4 · Cited by 1,189
Impact of Obesity on Plasma Natriuretic Peptide Levels
Wang, T. J., Larson, M. G., Levy, D., Benjamin, E. J., Leip, E. P., Wilson, P. W. F., & Vasan, R. S. (2004) · Circulation · doi:10.1161/01.cir.0000112582.16683.ea · Cited by 1,022
Effect of valsartan on the incidence of diabetes and cardiovascular events
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001121 · Cited by 660 · cited 1×
“Among patients with impaired glucose tolerance and cardiovascular disease or risk factors, the use of valsartan for 5 years, along with lifestyle modification, led to a 14% relative reduction in T2DM incidence.(21) However, ramipril compared with placebo did not reduce the risk of new onset T2DM in patients with impai…”
BackgroundDoehner, W., Rauchhaus, M., Ponikowski, P., Godsland, I. F., von Haehling, S., Okonko, D. O., Leyva, F., Proudler, A. J., Coats, A. J. S., & Anker, S. D. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.02.093 · Cited by 294 · cited 1×
“Decreased skeletal muscle oxidative capacity in heart failure is prevalent and clinically relevant because poor exercise tolerance and impaired insulin sensitivity predict mortality risk in these patients.(37) Therefore, metabolic improvements with sacubitril/valsartan may also be beneficial in patients with heart fai…”
BackgroundMiyashita, K., Itoh, H., Tsujimoto, H., Tamura, N., Fukunaga, Y., Sone, M., Yamahara, K., Taura, D., Inuzuka, M., Sonoyama, T., et al. (2009) · Diabetes · doi:10.2337/db09-0393 · Cited by 288
Contribution of Major Lifestyle Risk Factors for Incident Heart Failure in Older Adults
Del Gobbo, L. C., Kalantarian, S., Imamura, F., Lemaitre, R., Siscovick, D. S., Psaty, B. M., & Mozaffarian, D. (2015) · JACC: Heart Failure · doi:10.1016/j.jchf.2015.02.009 · Cited by 186
Fryer, R. M., Segreti, J., Banfor, P. N., Widomski, D. L., Backes, B. J., Lin, C. W., Ballaron, S. J., Cox, B. F., Trevillyan, J. M., Reinhart, G. A., et al. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707641 · Cited by 130
Goossens, G. H., Blaak, E. E., Saris, W. H. M., & van Baak, M. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032053 · Cited by 84
Self-citation
Cited by
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473
Self-citationOparil, S., Acelajado, M. C., Bakris, G. L., Berlowitz, D. R., Cífková, R., Dominiczak, A. F., Grassi, G., Jordan, J., Poulter, N. R., Rodgers, A., et al. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.14 · Cited by 1,167
Self-citationSeferovic, J. P., Claggett, B., Seidelmann, S. B., Seely, E. W., Packer, M., Zile, M. R., Rouleau, J. L., Swedberg, K., Lefkowitz, M., Shi, V. C., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30087-6 · Cited by 352
Jordan, J., Birkenfeld, A. L., Melander, O., & Moro, C. (2018) · Hypertension · doi:10.1161/hypertensionaha.118.11081 · Cited by 68
Self-citationChobanyan-Jürgens, K., Scheibe, R. J., Potthast, A. B., Hein, M., Smith, A., Freund, R., Tegtbur, U., Das, A. M., Engeli, S., Jordan, J., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00411 · Cited by 24
Self-citation
Metadata
- Authors
- Jordan, J., Stinkens, R., Jax, T., Engeli, S., Blaak, E., May, M., Havekes, B., Schindler, C., Albrecht, D., Pal, P., Heise, T., Goossens, G., & Langenickel, T.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2016-11-17
- Volume
- 101
- Issue
- 2
- Pages
- 254-263
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2513218697
- Cited by
- 123
- References
- 11
- FWCI
- 10.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Improved Insulin Sensitivity With Angiotensin Receptor Neprilysin Inhibition in Individuals With Obesity and Hypertension. https://app.cochat.ai/papers/10.1002/cpt.455
- The paper
- Jordan, J., Stinkens, R., Jax, T., Engeli, S., Blaak, E., May, M., Havekes, B., Schindler, C., Albrecht, D., Pal, P., Heise, T., Goossens, G., & Langenickel, T. (2017). Improved Insulin Sensitivity With Angiotensin Receptor Neprilysin Inhibition in Individuals With Obesity and Hypertension. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.455
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.